WO2003029251A1 - Novel process for the synthesis of thiazolidinedione derivatives - Google Patents
Novel process for the synthesis of thiazolidinedione derivatives Download PDFInfo
- Publication number
- WO2003029251A1 WO2003029251A1 PCT/IN2001/000163 IN0100163W WO03029251A1 WO 2003029251 A1 WO2003029251 A1 WO 2003029251A1 IN 0100163 W IN0100163 W IN 0100163W WO 03029251 A1 WO03029251 A1 WO 03029251A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- synthesis
- reaction
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to process of preparing thiazolidinedione derivatives of formula I known for the treatment of non-insulin dependent diabetes.
- Non-insulin-dependent diabetes mellitus is a metabolic 0 disorder leading to long-term complications and premature atherosclerosis.
- EP 0 306 228 describes such a procedure for the synthesis of a number of thiazolidinedione derivatives.
- US patent 5,726,055 describes a process wherein a yeast reductase, R odotorula giutinis the microbial reductase source for the reduction of the benzylidine group to the desired product.
- WO 99/23095 describes a process using a noble metal mediated reduction for the benzylidine group while, EP 0306 228 discloses a process for the benzylidine group reduction using dissolving metal methods.
- the present invention details a process for the preparation of compounds of formula I,
- This invention particularly relates to a process for the preparation of thiazolidinedione derivatives of the general formula L
- step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
- step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
- step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH 4 -
- step (ii) is carried in tetrahydrofuran.
- Ar is an unsubstituted or substituted heteroaryl
- X can be either CH or N
- R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH 3 and G is either F or OH
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compounds of formula (I), which are useful in the treatment of non-insulin dependent diabetes, and wherein Ar is optionally substituted heteroaryl, X is CH or N, R is H or alkyl, and n is 1 or 2, are prepared by reacting compounds of formula (II) with compounds of formula (VI) wherein G is OH or F.
Description
TITLE OF THE INVENTION
Novel Process for tile synthesis of thiazolidinedione derivatives
FIELD OF THE INVENTION
$ The present invention relates to process of preparing thiazolidinedione derivatives of formula I known for the treatment of non-insulin dependent diabetes. BACKGROUND OF THE INVENTION
Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic 0 disorder leading to long-term complications and premature atherosclerosis.
Compounds of class like, sulfonylureas, biguanides were used for treatment of patients suffering from such disorders. Substituted 5- arylthiazolidinediones demonstrated potent activity towards non-insulin s dependent diabetes. European patent application numbers 0 008 203, 0 139 421, 0 155 845, 0 177 353, 0 193 256, 0 207 581, 0 208420 and 0 306 228 describes a number of thiazolidinedione derivatives which are disclosed as having hypoglycemic and hypolipidaemic activity.
Traditionally the desired alcohol was first alkylated with the aryl o benzaidehyde followed by condensation with thiazolidinedione to give the benzylidine intermediate, which on hydrogenation afforded the desired product. EP 0 306 228 describes such a procedure for the synthesis of a number of thiazolidinedione derivatives.
US patent 5,726,055 describes a process wherein a yeast reductase, R odotorula giutinis the microbial reductase source for the reduction of the benzylidine group to the desired product. WO 99/23095 describes a process using a noble metal mediated reduction for the benzylidine group while, EP 0306 228 discloses a
process for the benzylidine group reduction using dissolving metal methods.
The present invention offers a more general procedure for the synthesis of variety of thiazolidinedione derivatives from a common intermediate, namely 5=(4-hydroxyphenyl)benzyl=2,4=thiazolidϊnedione, which can be alkylated with a suitable alcohol to give the desired pharmaceutical intermediate.
SUMMARY OF THE INVENTION
The present invention details a process for the preparation of compounds of formula I,
Formula I where Ar is a substituted or unsubstituted heteroaryl, X is CH or N, R is hydrogen or alkyl group and n is 1 or 2; is prepared by reacting a compound of formula II with a compound of formula VI, where G is F or OH, and Ar, X, R and n are defined with respect to formula I.
Compounds of formula VI are obtained by reacting a compound of formula IV with thiazolidinedione (formula III) as shown in scheme 1 in the presence of alumina/lithium hydroxide or in the presence of a base chosen from β-alanine, piperidine, pyridine and a solvent chosen from toluene, xylene etc to give a intermediate of formula V.
Formula V
Reacting a compound of formula V with magnesium in the presence of iodine in methanol or a reagent chosen from NaBHcCoCfe or MgBH4 or KBH4 or UBH4 in tetrahydrofuran as solvent to give an intermediate of formula VI as shown in the scheme 2
Formula VI
Reacting a compound of formula VI where G = F or OH with a compound of formula II to give a compound of formula I as shown in the scheme 3. DETAILED DESCRIPTION OF THE INVENTION
This invention particularly relates to a process for the preparation of thiazolidinedione derivatives of the general formula L
The process for the synthesis of compounds of formula I (where Ar is an unsubstituted or substituted heteroaryl, X can be either CH or N, R can be either H or alkyl, n is 1 when X is CH and R is H, n is 2 when X is N and R is CH3) comprising of reacting a compound of formula II (where Ar is an unsubstituted or substituted heteroaryl, X can be either CH or N, R can be either H or alkyl, n is 1 when X is CH and R is H, n is 2 when X is N and R is CH3) with a compound of formula VI (where G = F or OH). The process wherein the compound of formula VI (where G = F or
OH) is reacted with a compound of formula Ha to get a compound of formula la.
The process wherein the compound of formula VI (where G = F or OH) is reacted with a compound of formula lib to get a compound of formula lb.
The process wherein the reaction is carried out in the presence the potassium carbonate-dimethyl formamide, sodium hydride-dimethyl formamide or potassium carbonate-dimethyl sulphoxide.
The process wherein the reaction is carried out by using a compound of formula II where the alcoholic hydroxy group is substituted.
The process wherein the compound of formula VI (where G = F or OH) is prepared by:
(i) reacting a compound of formula III with a compound of formula IV(where G = F or OH) to give an intermediate of formula V (where G = F or OH) (ii) hydrogenating the intermediate V(where G = F or OH) in to get the compound of formula VI (where G = F or OH).
The process wherein the reaction in step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
The process wherein the reaction in step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
The process wherein the hydrogenation agent in step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH4-
C0CI2, MgBH4/ KBH4or LiBH4. The process wherein the hydrogenation in step (ii) is carried in tetrahydrofuran.
The invention is described with the help of the following examples not to be considered as limiting.
Example 1 Synthesis of 4-Hydroxybenzylidine-2,4-thiazolϊdinedione
(Formula V)
To a mixture of lOg of lithium hydroxide and 40g of basic alumina,
25g of 2,4-thiazolidinedione and 29.2 ml of 4-hydroxy benzaidehyde were added followed by 125ml of DMF. The contents were stirred at room temperature over a period of 24h. The reaction mixture was filtered and the alumina cake was washed with ethyl acetate. The combined filtrate was concentrated to remove ethyl acetate and DMF.
The gummy residue was triturated in isopropanol and the solid obtained
was filtered and washed thoroughly with isopropanol and dried to give 29g of the title compound in 64% yield. H NMR (DMSO) - 9.8 (s, 1H), 7.4 (d, 2H), 7.2 (s, 1H), 6.9 (d, 2H) Example 2
5 Synthesis of 5-(4-Fluorobenzγlidine)-2,4-thiazGlidinedione (Formula V )
To a mixture of lOg of lithium hydroxide and 40g of basic alumina, 25g of 2,4-thiazolidinedione and 29.2 ml of 4-fluorobenzaldehyde were added followed by 125ml of DMF. The contents were stirred at room o temperature over a period of 24h. The reaction mixture was filtered and the alumina cake was washed with ethyl acetate. The combined filtrate was concentrated to remove ethyl acetate and DMF. The gummy residue was dissolved in isopropanol and the solid obtained was filtered and washed thoroughly with isopropanol and dried to give 27g of the title s compound in 61% yield. *H NMR (DMSO) - 12.2 (s, 1H), 7.8 (s, 1H), 7.65 (m, 2H), 7.4 (m, 2H) Example 3
Synthesis of 5-(4~Hydroxyphenyl)-2,4-thiazolidinedione (Formula VI) o To a solution of 33g of cobalt chloride in 200 ml of water, 4%
NaOH (330mL) was added. The contents were stirred for 45min at RT and 8.8g of DMG dissolved in 100ml of THF was added over a period of 30min. lOg of the compound from example 1 was added and the contents were cooled to 5°C 8g of sodium borohydride was added in 5 portions and the reaction mixture was allowed to stir at 10°C for 24h. 10% charcoal in 50mL of acetone was added and the contents were stirred for lh and the reaction mixture was filtered through celite. The filtrate was acidified with acetic acid until the product precipitates and
the resulting solid was filtered and dried to give 7.5g of the compound melting at 154-156°C.
*H NMR (in DMSO) 2.9-3.0 (m, 1H), 3.2-3.3 (m, 1H), 4.8-4.9 (m, 1H),
6.65 (d, 2H), 7.0 (d, 2H), 9.4 (bs, 1H), 12 (bs, 1H) Example 4
Synthesis of 5-(4-Hydroxγphenγ!)-2,4-thiazolϊdinedione
(Formula VI)
To a solution of 5-(4-hydroxybenzylidine)-2,4-thiazolidinedione (5g in 125ml of methanol), magnesium turnings (5g) was added. The reaction mixture was stirred vigorously for 2h at room temperature.
Vigorous effervescence was observed and the temperature of the reaction mixture rose to 65oc. The stirring was continued for 2h. The reaction mixture was diluted with 100ml of water. The solid was filtered and the filtrate was extracted into 500ml of ethyl acetate. The organic layer was washed with water, brine, dried and concentrated to yield 3g of the desired product.
*H NMR (in DMSO) 2.9-3.0 (m, 1H), 3.2-3.3 (m, 1H), 4.8-4.9 (m, 1H),
6.65 (d, 2H), 7.0 (d, 2H), 9.4 (bs, 1H), 12 (bs, 1H)
Example 5 Synthesis of 5-{4-[(5-Ethyl-2-pyridyl)ethoxγ]benzyl}-2,4- thiazolidinedione (Formula la)
To a stirred solution of 2-(5-ethylpyridiyl)ethanol 5g in DMF (50ml) under an atmosphere of argon, sodium hydride was added in portions.
After the vigorous reaction subsided, the compound from example 4 was added and the reaction mixture was refluxed at 90-110°C for 24h. The reaction mixture was cooled to 0-5°C, excess hydride quenched with water, DMF was removed under reduced pressure and the residue was extracted with ethyl acetate. The organic extracts were washed with
water, brine and dried. Upon removal of the solvent the title compound was obtained in 62% yield.
Example 6
Synthesis of 5-{4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl}-2,4-thiazolidinedione (Formula lb)
To a stirred solution of 2-(N-methyl-N-(2-pyriylamino)ethanol 5g in DMF (50ml) under an atmosphere of argon, sodium hydride was added in portions. After the vigorous reaction subsided, the compound from example 4 was added and the reaction mixture was refluxed at 90-110°C for 24h. The reaction mixture was cooled to 0-5°C, excess hydride quenched with water, DMF was removed under reduced pressure and the residue was extracted with ethyl acetate. The organic extracts were washed with water, brine and dried. Upon removal of the solvent the title compound was obtained in 54% yield.
Scheme - 1
G = F or OH
Scheme - 2
G = F or OH
Scheme - 3
Where, Ar is an unsubstituted or substituted heteroaryl
X can be either CH or N
R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3 and G is either F or OH
Claims
1. A process for the synthesis of compounds of formula I
Formula I where Ar is an unsubstituted or substituted heteroaryl X can be either CH or N R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3
comprising of reacting a compound of formula II with a compound of formula VI
Formula II Formula VI where G = F or OH where, Ar is an unsubstituted or substituted heteroaryl X can be either CH or N
R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3
2. The process of claim 1, wherein the compound of formula VI, where G = F or OH is reacted with a compound of formula Ha to get a compound of formula la.
3. The process of claim 1, wherein the compound of formula VI, where G = F or OH is reacted with a compound of formula lib to get a compound of formula lb.
Formula lib Formula lb
4. The process of claim 1, wherein the reaction is carried out in the presence the potassium carbonate-dimethyl formamide, sodium hydride- dimethyl formamide or potassium carbonate- dimethyl sulphoxide.
5. The process of claim 1, wherein the compound of formula VI is prepared by:
Formula VI where G = F or OH (i) reacting a compound of formula III with a compound of formula IV to give an intermediate of
Formula III Formula IV where G = F or OH
(ii) hydrogenating the intermediate V in to get the compound of formula VI.
6. The process of claim 5, wherein the reaction in step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
7. The process of claim 5, wherein the reaction in step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
8. The process of claim 5, wherein the hydrogenation agent in step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH4- CoCI2, MgBH4, KBH4or LiBH4.
9. The process of claim 5, wherein the hydrogenation in step (ii) is carried in tetrahydrofuran.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2001/000163 WO2003029251A1 (en) | 2001-09-28 | 2001-09-28 | Novel process for the synthesis of thiazolidinedione derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2001/000163 WO2003029251A1 (en) | 2001-09-28 | 2001-09-28 | Novel process for the synthesis of thiazolidinedione derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003029251A1 true WO2003029251A1 (en) | 2003-04-10 |
Family
ID=11076382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2001/000163 Ceased WO2003029251A1 (en) | 2001-09-28 | 2001-09-28 | Novel process for the synthesis of thiazolidinedione derivatives |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2003029251A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005073227A3 (en) * | 2004-01-28 | 2005-09-22 | Usv Ltd | A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate |
| WO2006026934A1 (en) * | 2004-09-10 | 2006-03-16 | Zentiva, A.S. | Method for the preparation of rosiglitazone |
| WO2009148195A1 (en) * | 2008-06-02 | 2009-12-10 | Daebong Ls, Ltd. | 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same |
| WO2011133442A1 (en) * | 2010-04-19 | 2011-10-27 | Metabolic Solutions Development Company | Novel synthesis for thiazolidinedione compounds |
| WO2012021467A1 (en) * | 2010-08-10 | 2012-02-16 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| US8933240B2 (en) | 2010-08-10 | 2015-01-13 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002953A (en) * | 1987-09-04 | 1991-03-26 | Beecham Group P.L.C. | Novel compounds |
| GB2324089A (en) * | 1997-04-08 | 1998-10-14 | Nitto Chemical Industry Co Ltd | Process for the production of a thiazolidine derivative |
| WO2001012628A1 (en) * | 1999-08-17 | 2001-02-22 | Smithkline Beecham P.L.C. | Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
-
2001
- 2001-09-28 WO PCT/IN2001/000163 patent/WO2003029251A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002953A (en) * | 1987-09-04 | 1991-03-26 | Beecham Group P.L.C. | Novel compounds |
| GB2324089A (en) * | 1997-04-08 | 1998-10-14 | Nitto Chemical Industry Co Ltd | Process for the production of a thiazolidine derivative |
| WO2001012628A1 (en) * | 1999-08-17 | 2001-02-22 | Smithkline Beecham P.L.C. | Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation |
Non-Patent Citations (1)
| Title |
|---|
| GILES R G ET AL: "Regiospecific reduction of 5-benzylidene-2,4-thiazolidinediones and 4-oxo-2-thiazolidinethiones using lithium borohydride in pyridine and tetrahydrofuran", TETRAHEDRON, vol. 56, no. 26, June 2000 (2000-06-01), pages 4531 - 4537, XP004202146 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005073227A3 (en) * | 2004-01-28 | 2005-09-22 | Usv Ltd | A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate |
| WO2006026934A1 (en) * | 2004-09-10 | 2006-03-16 | Zentiva, A.S. | Method for the preparation of rosiglitazone |
| WO2009148195A1 (en) * | 2008-06-02 | 2009-12-10 | Daebong Ls, Ltd. | 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same |
| WO2011133442A1 (en) * | 2010-04-19 | 2011-10-27 | Metabolic Solutions Development Company | Novel synthesis for thiazolidinedione compounds |
| CN102947269A (en) * | 2010-04-19 | 2013-02-27 | 新陈代谢解决方案开发公司 | Novel synthesis for thiazolidinedione compounds |
| US8937182B2 (en) | 2010-04-19 | 2015-01-20 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| AU2011242956B2 (en) * | 2010-04-19 | 2015-01-22 | Cirius Therapeutics, Inc. | Novel synthesis for thiazolidinedione compounds |
| CN102947269B (en) * | 2010-04-19 | 2015-11-25 | 新陈代谢解决方案开发公司 | A New Synthetic Method of Thiazolidinedione Compounds |
| WO2012021467A1 (en) * | 2010-08-10 | 2012-02-16 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| US8895748B2 (en) | 2010-08-10 | 2014-11-25 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| US8933240B2 (en) | 2010-08-10 | 2015-01-13 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
| US8946435B2 (en) | 2010-08-10 | 2015-02-03 | Metabolic Solutions Development Company, Llc | Synthesis for thiazolidinedione compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1277323C (en) | Thiazolidinedione derivatives, their production and use | |
| US7863300B2 (en) | Process to prepare pioglitazone via several novel intermediates | |
| WO2002051823A1 (en) | Process for the preparation of rosiglitazone maleate | |
| CN115448907B (en) | Compound for treating peptic ulcer, intermediate and preparation method thereof | |
| EP1756099B1 (en) | Synthesis of antidiabetic rosiglitazone derivatives | |
| WO2003029251A1 (en) | Novel process for the synthesis of thiazolidinedione derivatives | |
| KR20000071138A (en) | Process for the Preparation of Substituted Thiazolidinedione | |
| NZ243651A (en) | Process for stereo-selective preparation of chiral thiazolidine-2,4-dione | |
| EP1551831A4 (en) | PROCESS FOR PREPARING THE RISPERIDONE | |
| WO2009148195A1 (en) | 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same | |
| US6632947B2 (en) | Process for the preparation of substituted thiazolidinedione | |
| US8993773B2 (en) | Process to prepare pioglitazone via several novel intermediates | |
| US20050043539A1 (en) | Process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate | |
| US7199240B2 (en) | Reductive alkylation of saturated cyclic amines | |
| WO2006126790A1 (en) | Processes for preparing 6,7,8-trihydroxy-1-(hydroxymethyl)-3-oxo-2-oxa-4-azabicyclo[3.3.1]nonane | |
| KR100697983B1 (en) | New intermediates and method for producing pioglitazone using the same | |
| EP1786808B1 (en) | Method for the preparation of rosiglitazone | |
| CN1978428B (en) | Method for preparing (3R, %S)-Fluvastatin | |
| JP2967989B2 (en) | Tetrahydropyridine derivative and production method thereof | |
| US20070225501A1 (en) | Process for the Preparation of Rosiglitazone | |
| EP4071139A1 (en) | Crystalline lofexidine hydrochloride | |
| EP2118095B1 (en) | A method for the preparation of zolmitriptan | |
| KR101164429B1 (en) | Manufacturing method for pioglitazone HCl | |
| JP4447742B2 (en) | Method for producing 3-mercapto-1- (1,3-thiazolin-2-yl) azetidine | |
| CN115894338A (en) | Method for preparing Ritlecetinib intermediate by coupling chemical enzyme and biological enzyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG US |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |